Cancer Research Grants Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morrissey, C.
Right arrow Articles by Maher, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrissey, C.
Right arrow Articles by Maher, E. R.
[Cancer Research 61, 7277-7281, October 1, 2001]
© 2001 American Association for Cancer Research

Molecular Biology and Genetics

Epigenetic Inactivation of the RASSF1A 3p21.3 Tumor Suppressor Gene in Both Clear Cell and Papillary Renal Cell Carcinoma1

Catherine Morrissey, Alonso Martinez, Malgorzata Zatyka, Angelo Agathanggelou, Sofia Honorio, Dewi Astuti, Neil V. Morgan, Holger Moch, Frances M. Richards, Takeshi Kishida, Masahiro Yao, Peter Schraml, Farida Latif and Eamonn R. Maher

Section of Medical and Molecular Genetics, Department of Pediatrics and Child Health [C. M., A. M., M. Z., A. A., S. H., D. A., N. V. M., F. M. R., F. L., E. R. M.], and CRC Renal Molecular Oncology Research Group [N. V. M., F. M. R., F. L., E. R. M.], University of Birmingham, The Medical School, Birmingham B15 2TT, United Kingdom; Institute for Pathology, University of Basel, CH-4003 Basel, Switzerland [H. M., P. S.]; and Yokohama City University School of Medicine, Yokohama City, Japan 236-0004 [T. K., M. Y.]

Renal cell carcinoma (RCC), the most common adult kidney neoplasm, is histopathologically heterogeneous, with most sporadic RCCs (~80%) classified as clear cell (CC) tumors. Chromosome 3p allele loss is the most frequent genetic alteration in RCC but is associated specifically with sporadic and hereditary forms of clear cell RCC (CC-RCC) and is not a feature of non-CC-RCC, such as papillary (chromophilic) RCC. The VHL tumor suppressor gene (TSG) maps to chromosome 3p25, and somatic inactivation of the VHL gene occurs in up to 70% of CC-RCC tumors and cell lines. However, VHL inactivation is not sufficient for CC-RCC tumorigenesis, and inactivation of 3p12–p21 TSG(s) appears to be necessary in CC-RCC irrespective of VHL gene inactivation status. Recently, we demonstrated that the candidate 3p21 TSG, RASSF1A, is hypermethylated in most small cell lung cancers. We have now investigated the role of RASSF1A inactivation in primary RCC tumors. RASSF1A promoter methylation was detected in 23% (32 of 138) of primary CC-RCC tumors. In CC-RCC cell lines, RASSF1A methylation was associated with silencing of RASSF1A expression and restoration of expression after treatment with 5'-azacytidine. The frequency of RASSF1A methylation was similar in CC-RCC with and without VHL gene inactivation (24% versus 21%), and there was no association between epigenetic silencing of the RASSF1A and VHL TSGs, because 0 of 6 tumors with VHL hypermethylation had RASSF1A methylation, and VHL was not methylated in 26 CC-RCCs with RASSF1A methylation. Although 3p allele loss has been reported rarely in papillary RCC, we identified RASSF1A methylation in 44% (12 of 27) of papillary RCCs analyzed. Thus: (a) inactivation of RASSF1A is a frequent event in both CC-RCC and papillary RCC tumors; (b) there is no relationship between epigenetic silencing of RASSF1A and VHL inactivation status in CC-RCC. Fifty-four CC-RCCs analyzed for RASSF1A methylation were informative for 3p21 allele loss, and 20% (7 of 35) with 3p21 allele loss demonstrated RASSF1A methylation. All informative CC-RCCs with 3p21 allele loss and no RASSF1A methylation also demonstrated allele losses at other regions of 3p so that tumorigenesis in these cases may result from: (a) haploinsufficiency of RASSF1A; (b) inactivation of other 3p21 TSGs; or (c) inactivation of 3p TSGs from outside of 3p21. RASSF1A is the first TSG to be inactivated frequently in both papillary and CC-RCCs. The finding of frequent epigenetic inactivation of RASSF1A in papillary RCCs despite previous studies reporting infrequent 3p21 allele loss in this tumor type illustrates how the systematic identification of all major human cancer genes will require detailed analysis of the cancer genome and epigenome.




This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
T. Fujita, J. Igarashi, E. R. Okawa, T. Gotoh, J. Manne, V. Kolla, J. Kim, H. Zhao, B. R. Pawel, W. B. London, et al.
CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas
J Natl Cancer Inst, July 2, 2008; 100(13): 940 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
I. Peters, B. Vaske, K. Albrecht, M. A. Kuczyk, U. Jonas, and J. Serth
Adiposity and Age are Statistically Related to Enhanced RASSF1A Tumor Suppressor Gene Promoter Methylation in Normal Autopsy Kidney Tissue
Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2526 - 2532.
[Abstract] [Full Text] [PDF]

Home page
 Brief Funct Genomic ProteomicHome page
D. Angeloni
Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease
Brief Funct Genomic Proteomic, May 24, 2007; (2007) elm007v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Ibanez de Caceres, E. Dulaimi, A. M. Hoffman, T. Al-Saleem, R. G. Uzzo, and P. Cairns
Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
Cancer Res., May 15, 2006; 66(10): 5021 - 5028.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Balch, P. Yan, T. Craft, S. Young, D. G. Skalnik, T. H-M. Huang, and K. P. Nephew
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
Mol. Cancer Ther., October 1, 2005; 4(10): 1505 - 1514.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Morris, D. Gentle, M. Abdulrahman, E. N. Maina, K. Gupta, R. E. Banks, M. S. Wiesener, T. Kishida, M. Yao, B. Teh, et al.
Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma
Cancer Res., June 1, 2005; 65(11): 4598 - 4606.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Agathanggelou, W. N. Cooper, and F. Latif
Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers
Cancer Res., May 1, 2005; 65(9): 3497 - 3508.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Ahmed-Choudhury, A. Agathanggelou, S. L. Fenton, C. Ricketts, G. J. Clark, E. R. Maher, and F. Latif
Transcriptional Regulation of Cyclin A2 by RASSF1A through the Enhanced Binding of p120E4F to the Cyclin A2 Promoter
Cancer Res., April 1, 2005; 65(7): 2690 - 2697.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Tommasi, R. Dammann, Z. Zhang, Y. Wang, L. Liu, W. M. Tsark, S. P. Wilczynski, J. Li, M. You, and G. P. Pfeifer
Tumor Susceptibility of Rassf1a Knockout Mice
Cancer Res., January 1, 2005; 65(1): 92 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Eckfeld, L. Hesson, M. D. Vos, I. Bieche, F. Latif, and G. J. Clark
RASSF4/AD037 Is a Potential Ras Effector/Tumor Suppressor of the RASSF Family
Cancer Res., December 1, 2004; 64(23): 8688 - 8693.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. Das and R. Singal
DNA Methylation and Cancer
J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Gonzalgo, S. Yegnasubramanian, G. Yan, C. G. Rogers, T. L. Nicol, W. G. Nelson, and C. P. Pavlovich
Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis
Clin. Cancer Res., November 1, 2004; 10(21): 7276 - 7283.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Dulaimi, I. I. de Caceres, R. G. Uzzo, T. Al-Saleem, R. E. Greenberg, T. J. Polascik, J. S. Babb, W. E. Grizzle, and P. Cairns
Promoter Hypermethylation Profile of Kidney Cancer
Clin. Cancer Res., June 15, 2004; 10(12): 3972 - 3979.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Struckmann, P. Schraml, R. Simon, K. Elmenhorst, M. Mirlacher, J. Kononen, and H. Moch
Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma
Cancer Res., March 1, 2004; 64(5): 1632 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. H. N. Wong, J. Chan, J. Wong, and P. K. H. Tam
Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia1
Clin. Cancer Res., February 1, 2004; 10(3): 994 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. L. Fenton, A. Dallol, A. Agathanggelou, L. Hesson, J. Ahmed-Choudhury, S. Baksh, C. Sardet, R. Dammann, J. D. Minna, J. Downward, et al.
Identification of the E1A-Regulated Transcription Factor p120E4F as an Interacting Partner of the RASSF1A Candidate Tumor Suppressor Gene
Cancer Res., January 1, 2004; 64(1): 102 - 107.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Battagli, R. G. Uzzo, E. Dulaimi, I. Ibanez de Caceres, R. Krassenstein, T. Al-Saleem, R. E. Greenberg, and P. Cairns
Promoter Hypermethylation of Tumor Suppressor Genes in Urine from Kidney Cancer Patients
Cancer Res., December 15, 2003; 63(24): 8695 - 8699.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
N Fernandes da Silva, D Gentle, L B Hesson, D G Morton, F Latif, and E R Maher
Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer
J. Med. Genet., November 1, 2003; 40(11): 820 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Agathanggelou, I. Bieche, J. Ahmed-Choudhury, B. Nicke, R. Dammann, S. Baksh, B. Gao, J. D. Minna, J. Downward, E. R. Maher, et al.
Identification of Novel Gene Expression Targets for the Ras Association Domain Family 1 (RASSF1A) Tumor Suppressor Gene in Non-Small Cell Lung Cancer and Neuroblastoma
Cancer Res., September 1, 2003; 63(17): 5344 - 5351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Zhong, W. Yeo, M. W. Tang, N. Wong, P. B. S. Lai, and P. J. Johnson
Intensive Hypermethylation of the CpG Island of Ras Association Domain Family 1A in Hepatitis B Virus-associated Hepatocellular Carcinomas
Clin. Cancer Res., August 1, 2003; 9(9): 3376 - 3382.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Sukosd, N. Kuroda, T. Beothe, A. P. Kaur, and G. Kovacs
Deletion of Chromosome 3p14.2-p25 Involving the VHL and FHIT Genes in Conventional Renal Cell Carcinoma
Cancer Res., January 15, 2003; 63(2): 455 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Dallol, N. F. Da Silva, P. Viacava, J. D. Minna, I. Bieche, E. R. Maher, and F. Latif
SLIT2, a Human Homologue of the Drosophila Slit2 Gene, Has Tumor Suppressor Activity and Is Frequently Inactivated in Lung and Breast Cancers
Cancer Res., October 15, 2002; 62(20): 5874 - 5880.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. E. Lusher, J. C. Lindsey, F. Latif, A. D. J. Pearson, D. W. Ellison, and S. C. Clifford
Biallelic Epigenetic Inactivation of the RASSF1A Tumor Suppressor Gene in Medulloblastoma Development
Cancer Res., October 15, 2002; 62(20): 5906 - 5911.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
D. Bodmer, W. van den Hurk, J. J. M. van Groningen, M. J. Eleveld, G. J. M. Martens, M. A. J. Weterman, and A. Geurts van Kessel
Understanding familial and non-familial renal cell cancer
Hum. Mol. Genet., October 1, 2002; 11(20): 2489 - 2498.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Kuzmin, J. W. Gillespie, A. Protopopov, L. Geil, K. Dreijerink, Y. Yang, C. D. Vocke, F.-M. Duh, E. Zabarovsky, J. D. Minna, et al.
The RASSF1A Tumor Suppressor Gene Is Inactivated in Prostate Tumors and Suppresses Growth of Prostate Carcinoma Cells
Cancer Res., June 1, 2002; 62(12): 3498 - 3502.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.